Danish biotech firm Symphogen enters multi-million dollar American partnership deal

The Danes will receive upfront payment and potential royalties for R&D efforts

The Danish biotech company Symphogen has entered into a strategic collaboration agreement with the US firm Baxalta that will see the Danes receive 175 million dollars (1.2 billion kroner) upfront, with the potential for future payments and royalties.

Symphogen specialises in antibody therapeutics for the treatment of cancer while Baxalta works with therapies for orphan diseases and underserved conditions in hematology, oncology and immunology.

Different strengths
According to the terms of the partnership, Symphogen will work on the development of six so-called novel immune checkpoint therapies in the treatment of rare diseases, whereafter Baxalta will have the exclusive option rights to commercialise the products worldwide.

Kirsten Drejer, the CEO of Symphogen, said the two parties brought different strengths to the table.

“Baxalta’s dedication to delivering transformative therapies and its global commercial presence make it an ideal strategic partner for Symphogen, as we complement Baxalta with R&D competencies within the immuno-oncology area,” she said.

“We look forward to providing Baxalta with innovative immuno-oncology product candidates under this broad collaboration.”





  • How internationals can benefit from joining trade unions

    How internationals can benefit from joining trade unions

    Being part of a trade union is a long-established norm for Danes. But many internationals do not join unions – instead enduring workers’ rights violations. Find out how joining a union could benefit you, and how to go about it.

  • Internationals in Denmark rarely join a trade union

    Internationals in Denmark rarely join a trade union

    Internationals are overrepresented in the lowest-paid fields of agriculture, transport, cleaning, hotels and restaurants, and construction – industries that classically lack collective agreements. A new analysis from the Workers’ Union’s Business Council suggests that internationals rarely join trade unions – but if they did, it would generate better industry standards.

  • Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    The numbers are especially striking amongst the 3,477 business and economics students polled, of whom 31 percent elected Novo Nordisk as their favorite, compared with 20 percent last year.